# Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

> **NCT01938430** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 339 (actual)

## Conditions studied

- Chronic HCV Infection

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01938430
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-03
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01938430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01938430, "Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01938430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*